Abstract Details

Title Improvement in Patient-Reported SymptoMScreen Scores Among Ocrelizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Results From the CASTING Clinical Trial

Topic Multiple Sclerosis

Presentation(s) P6 - Poster Session 6 (12:00 PM-1:00 PM)

Poster/Presentation
Number 9-009

Objective

To report 1-year changes in SymptoMScreen scores among patients with multiple sclerosis (MS) enrolled into the CASTING trial (NCT02861014).

Background

SymptoMScreen is a patient-reported outcome designed to rapidly assess symptom limitations across 12 domains commonly affected by MS (walking, dexterity, spasticity, bodily pain, sensory, bladder function, fatigue, vision, vestibular, cognitive, depression and anxiety). Each domain is scored on 7-point Likert scale (0 [not affected] to 6 [total limitation]) and domain scores are summed to calculate a total score. SymptoMScreen is used in the ongoing, open-label, single-arm, Phase IIIb CASTING clinical trial.

Design/Methods

In CASTING, patients with relapsing-remitting MS (Expanded Disability Status Scale [EDSS] score ≤4.0 at screening; disease duration ≤10 years), who had a suboptimal response to ≥1 disease-modifying therapy (DMT), receive ocrelizumab 600 mg/24 weeks intravenously for 96 weeks (first dose, 2×300 mg, 14 days apart). SymptoMScreen was performed at baseline and Week 48 (1-year interim data).

Results

Patients (N=680; female, 64%; baseline EDSS [SD], 2.1 [1.1]); mean (SD) disease duration of 5.0 (2.7) years; 61% had received only one DMT prior to enrolment (most frequently, interferon-beta [29%]). At Week 48, SymptoMScreen total mean (SD) score significantly improved (p<0.001) from 15.19 (12.66) to 13.79 (11.95). Statistically significant improvements from baseline were observed for sensory symptoms (-0.31; p<0.001), vision (-0.23; p<0.001), fatigue (-0.21; p<0.001), dizziness (-0.14; p=0.004), cognition (-0.13; p=0.002), walking (-0.09; p=0.023), hand function (-0.08; p=0.037) and depression (-0.09; p=0.04) domains, while other domains showed improvements from baseline that did not reach statistical significance (p>0.05): spasticity (-0.02), bodily pain (-0.06), bladder control (-0.07) and anxiety (-0.01) domains.

Conclusions

Patients with MS and a suboptimal response to therapy who switched to ocrelizumab experienced symptomatic improvement after 1 year, which was most pronounced in sensory, fatigue and vision domains.

Authors/Disclosures
Ilya Kister, MD, F�鶹��ýӳ�� (NYU School of Medicine) PRESENTER	Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Regine Buffels, MD	Dr. Buffels has nothing to disclose.
Susanne Clinch	Susanne Clinch has stock in F. Hoffmann-La Roche.
	No disclosure on file
Patrick Vermersch (CHR de Lille)	Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS-Celgene. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ad Scientiam. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for La revue des microbiotes. The institution of Patrick Vermersch has received research support from Roche. The institution of Patrick Vermersch has received research support from Sanofi.

�鶹��ýӳ��

�鶹��ýӳ��